Precision-fermented infant formula

01Overview and value chain

Markers: [EC: FDA GRAS 21 CFR 170.30 no-questions letters, EU Novel Food Regulation (EC) 2015/2283, China GB 25596-2025 & 《生牛乳乳铁蛋白分级》 | OECD: Food Systems | Regulator: FDA (USA), EFSA (EU), NHC (China)]

Precision-fermented infant formula is the application of engineered-microbe fermentation to the bioactive proteins that distinguish breast milk from cow’s-milk formula — above all lactoferrin, an iron-binding glycoprotein that makes up only about 1 percent of whey proteins and is so scarce in cow’s milk that thousands of litres are needed to isolate a single kilogram, pushing bovine lactoferrin prices above 650 US dollars a kilo and earning it the traders’ nickname “pink gold”. By inserting the lactoferrin gene into a food-grade yeast such as Komagataella phaffii (formerly Pichia pastoris) or a filamentous fungus such as Trichoderma reesei, producers can now brew bioidentical bovine lactoferrin and, harder, human-identical lactoferrin in stainless-steel tanks, decoupling supply from dairy herds. The global lactoferrin market of roughly 700 million US dollars, growing at more than 7 percent a year, feeds primarily into premium infant formula, the largest slice of a 90 billion US dollar formula industry that bioactive proteins are widely expected to restructure over the next decade. The technology moved from proof-of-concept to commercial deployment in 2025-2026: TurtleTree received the first US FDA GRAS “no-questions” letter for a precision-fermented lactoferrin in March 2025, All G followed in April 2026, Vivici launched Vivitein LF with self-affirmed GRAS in early 2026, and the Nestlé-Helaina (June 2026) and Novonesis-TurtleTree (July 2026) partnerships began routing precision-fermented lactoferrin into finished early-life-nutrition products at multinational scale.

The key directions of precision-fermented infant formula are:

1. Human-identical lactoferrin (Human Lactoferrin): matching the human amino-acid sequence rather than the bovine one, so the infant body does not produce the antibodies seen against bovine lactoferrin — Helaina’s effera and Guoke Xinglian’s human-homologous lactoferrin, both brewed in food-grade yeast.
2. Bovine-identical lactoferrin at scale (Bovine LF Scale-up): recombinant bovine lactoferrin bioidentical to the cow’s-milk molecule but tank-produced — TurtleTree LF+, All G LFX, Vivici Vivitein LF, De Novo Foodlabs NanoFerrin — with cost projected to fall below conventional extraction by 2029.
3. Ingredient-to-brand partnerships (Brand Integration): the route from a B2B ingredient drum to a retail formula tin, run through multinational offtakers — Novonesis exclusively scales and commercializes TurtleTree’s LF+ for early-life nutrition, Nestlé co-develops formula with Helaina’s effera, Danone and Bel Group back Standing Ovation’s casein platform.
4. Integrated next-gen formula brands (Integrated Formula Brands): fully controlled, end-to-end infant-formula brands built around breast-milk science — ByHeart’s farm-to-formula manufacturing and 15 percent share of the addressable US market — that sit at the finished-product layer where precision-fermented bioactives land.

Sectoral value chain

[Gene design & strain engineering] ──> [Fed-batch yeast fermentation] ──> [Cell separation]
                                                          │
                                                 (Secreted lactoferrin)
                                                          │
                                                          ▼
[ spray-dried LF ingredient ] <── [Polishing & UF] <── [Disc-stack clarification]
              │
              ▼
[B2B supply to formula brands] ──> [Finished early-life nutrition]

Value chain levels

Cross-cutting technologies of the sector:

• Food-grade yeast expression (Yeast Expression Platform): Komagataella phaffii secretion of correctly folded, glycosylated human lactoferrin — Guoke Xinglian claims to be the only producer using food-grade yeast for human-homologous glycoproteins.
• Glycosylation fidelity (Human Glycosylation): reproducing the human-specific sugar-chain decoration that governs lactoferrin’s antibacterial, antiviral and proteolysis-resistance behaviour, the core technical barrier between bovine-identical and human-identical products.
• Cost-decoupled scale-up (Cost-Decoupled Scale): dairy-partner manufacturing (Novonesis for TurtleTree, Armor Protéines for All G, Ajinomoto/Tetra Pak for Standing Ovation) that lets fermentation startups reach multi-hundred-ton output without owning bioreactor fleets.

02US

The United States leads precision-fermented infant-formula ingredients both in regulatory clearances — the FDA “no-questions” GRAS letter is the global benchmark other markets align to — and in the integrated formula brands that consume them.

Human lactoferrin (Helaina), first GRAS lactoferrin (TurtleTree), integrated formula brand (ByHeart)

• Helaina effera: founded in New York by Laura Katz in 2019, Helaina brews human-identical lactoferrin (effera) in Komagataella phaffii and has published 11 papers on it; production has reached metric-ton scale (about 10 million servings per run) through co-manufacturing partners, and the company has raised more than 80 million US dollars. In June 2026 Nestlé announced a multi-year collaboration to develop infant formula with effera, the first time a global formula incumbent has built a product around precision-fermented human lactoferrin.
• TurtleTree LF+: Singapore-founded but US-commercially anchored, TurtleTree became the first company globally to receive an FDA GRAS “no-questions” letter for a precision-fermented lactoferrin (LF+, received 8 March 2025); in July 2026 Novonesis took exclusive rights to scale, manufacture and commercialize LF+ for the early-life-nutrition market, with Novonesis and Mitsui Chemicals’ 321Catalyst Ventures taking a minority stake.
• ByHeart (integrated formula brand): the finished-product offtaker layer — a breast-milk-science-based, end-to-end infant-formula brand that has raised 395 million US dollars (including 95 million in May 2024), built two domestic manufacturing facilities in Portland, Oregon and Allerton, Iowa, and ran the largest clinical trial by a new infant-formula brand in 25 years, reaching about 15 percent of the addressable US market through Thrive Market, Target and direct-to-consumer channels.

03CN

China is both the world’s largest infant-formula market and the place where precision-fermented lactoferrin meets a distinctive regulatory layer: a dairy-industry lactoferrin grading standard that formalises the protein as the marker of premium raw milk.

CAS-origin human lactoferrin (Guoke Xinglian), LF grading standard, special-medical-purpose formula

• Guoke Xinglian (国科星联): a Beijing biosynthesis company spun out of Chinese Academy of Sciences technology that precision-ferments human-homologous lactoferrin in food-grade yeast — positioning itself as the only producer using food-grade yeast to express human-homologous glycoproteins — alongside its A60 active peptide that reproduces a scarce breast-milk protein fragment. The company completed a hundred-million-yuan (about 200 million yuan cumulative) A+ round in January 2026 backed by Sequoia China, 中科创星, Legend Star and Gobi Ventures, explicitly framing lactoferrin as “from mothers, for the mother-and-infant market” across perinatal care, nutraceuticals and infant formula.
• Raw-milk lactoferrin grading standard: the agricultural industry standard 《生牛乳乳铁蛋白分级》 classifies raw cow’s milk by lactoferrin content (premium grade at least 80 mg per kilogram), making lactoferrin the quality identifier that pushes formula brands from late-stage addition toward native-rich sourcing — the demand signal that precision-fermented lactoferrin is positioned to meet on cost and consistency.
• GB 25596-2025 & the formula innovation forum: the revised national standard for special-medical-purpose infant formula (adding ketogenic and anti-reflux categories, capping sucrose) and the China Centre for Disease Control and Prevention-led infant-formula innovation forum (supported by Yili/伊利, October 2025) anchor the regulatory and scientific frame into which biosynthesized lactoferrin is entering.

04EU

Europe brings the largest industrial-fermentation incumbents and the consortium-scale public funding that lets precision-fermented dairy proteins move from startup pilots toward multi-hundred-ton output, even as the EU Novel Food Regulation keeps the regulatory clock slower than the US GRAS path.

Vivici lactoferrin (NL), Standing Ovation casein (FR), PFx Biotech & HuMiLAF

• Vivici (Netherlands): the Delft-based precision-fermentation company backed by Fonterra and DSM-Firmenich launched Vivitein LF in the United States in 2026 with self-affirmed GRAS status (February 2026) and, in June 2026, secured a 12.5 million euro European Innovation Council Accelerator grant to scale precision-fermented dairy proteins including lactoferrin — the largest single EU public commitment to the category.
• Standing Ovation (France): the Paris casein-fermentation company founded in 2020 closed a 34 million US dollar (about 30 million euro) Series B in March 2026 co-led by Bpifrance and Crédit Mutuel Innovation with Danone Ventures and Bel Group joining, targeting FDA no-questions GRAS by end of 2026 and EFSA novel-food approval by end of 2027 for its alpha-s1, alpha-s2 and beta-casein ingredients used across protein bars, nutraceuticals and infant nutrition.
• PFx Biotech & HuMiLAF: the Portuguese startup PFx Biotech has raised about 2.5 million euro to develop highly bioactive human milk proteins through precision fermentation, while the EU-backed HuMiLAF consortium is scaling human lactoferrin production to pre-industrial levels — together seeding the next European generation of human-identical breast-milk bioactives.

05Leading companies and research institutes

06Tech stack and innovations

The precision-fermented infant-formula stack rests on three integrated layers: a production host that folds and secretes a complex glycoprotein, a downstream train that delivers food-grade purity, and an industrial-commercial architecture that bridges the startup-to-tonnage gap through dairy-partner manufacturing.

1. Expression hosts (Yeast & Fungal Platforms):
   • Komagataella phaffii (formerly Pichia pastoris) is the workhorse for human lactoferrin (Helaina effera, Guoke Xinglian) because its secretion pathway glycosylates and folds eukaryotic proteins efficiently on simple glucose/methanol feed.
   • casein and bovine-lactoferrin producers also use Trichoderma reesei and engineered Saccharomyces strains; Standing Ovation has demonstrated alpha-s1, alpha-s2 and beta-casein expression across fungal, yeast and bacterial hosts.
   • 2026 state of the art: chaperone-pathway CRISPR editing to prevent misfolding and aggregation of recombinant milk proteins during high-density fermentation, lifting secreted titres.
2. Glycosylation fidelity (Human Glycosylation Replication):
   • the decisive technical gap between bovine-identical and human-identical lactoferrin is the human-specific sugar-chain decoration; Guoke Xinglian frames its food-grade-yeast human glycoprotein expression as the barrier that lets human lactoferrin avoid the antibody response observed against bovine lactoferrin.
   • Helaina’s clinical work shows consumers of its human lactoferrin do not produce the antibodies the body raises against bovine lactoferrin, validating the glycosylation-matched approach.
3. Partner-decoupled scale-up (Partner Scale-up Model):
   • rather than building owned bioreactor fleets, precision-fermentation startups route scaling through dairy and biosolutions incumbents — Novonesis for TurtleTree LF+, Armor Protéines for All G, Ajinomoto and Tetra Pak for Standing Ovation — targeting hundreds of tons per year (De Novo Foodlabs’ PFerrinX26 joint venture with EFFV aims at 300 tons of bovine lactoferrin per year within a decade).

07Value chains and production pipelines

Industrial pipeline of a precision-fermented human lactoferrin ingredient for infant formula (FDA GRAS 21 CFR 170.30 / EU Novel Food (EC) 2015/2283)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Strain engineering     │ ───> │ 2. Fed-batch fermentation │
│    (K. phaffii + LF gene) │      │    (stainless bioreactor) │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. UF & polishing         │ <─── │ 3. Disc-stack              │
│    (15-20x concentration) │      │    clarification           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Spray drying & B2B bag │ ───> │ 6. Formula integration &  │
│    (GRAS / Novel Food)    │      │    retail early-life food  │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Strain engineering

A codon-optimised gene for human (or bovine) lactoferrin is cloned into a food-grade Komagataella phaffii host under a secretion signal, with chaperone-pathway tuning so the glycoprotein folds and is secreted into the broth rather than accumulating inside the cell. Duration: strain development is months; a single verified production clone then seeds all campaigns.

Stage 2: Fed-batch fermentation

The production strain is grown in a stainless-steel bioreactor on glucose (and methanol where an AOX1 promoter drives expression) at controlled pH, temperature and aeration; the yeast secretes lactoferrin into the broth, reaching multi-gram-per-litre titres at metric-ton output scale — Helaina reports about 10 million servings per production run. Duration: 5-8 days per batch.

Stage 3: Disc-stack clarification

The broth passes through disc-stack centrifuges that separate the producer yeast (directed to animal-feed recovery) from the lactoferrin-rich supernatant, which is cooled to protect the protein from proteolysis.

Stage 4: Ultrafiltration and polishing

Tangential-flow ultrafiltration concentrates the lactoferrin 15-20× while letting water, salts and low-molecular-weight metabolites pass through; anion-exchange or activated-carbon polishing removes residual host DNA and pigment to meet US GRAS and EU non-GMO purity expectations.

Stage 5: Spray drying and B2B packaging

The purified concentrate is spray-dried into a free-flowing powder with greater than 95 percent protein content and packed in sterile B2B packaging, carrying its FDA GRAS no-questions letter (TurtleTree March 2025, All G April 2026) or self-affirmed GRAS dossier (Vivici February 2026) for the formula-manufacturer customer.

Stage 6: Formula integration and retail early-life nutrition

The B2B lactoferrin is blended into a finished infant-formula matrix — alongside the protein base, vegetable oils, human milk oligosaccharides and the vitamin/mineral premix — by an integrated brand or incumbent (Nestlé with Helaina’s effera under their June 2026 collaboration; Novonesis commercializing TurtleTree LF+ for early-life nutrition), producing the retail tin or stick pack that closes the gap to breast milk.